Verzenio/abemaciclib Cost, Side effects, Dosage, Uses for certain advance Cancers.The FDA granted the approval of Verzenio to Eli Lilly and Company.
US FDA approved new drug Verzenio that contains active pharmaceutical ingredient abemaciclib for the treatment of certain advance metastatic cancers like hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer. US FDA approved this in combination with other drug fulvestrant if there is not adequate response after administering endocrine therapy.
Though it is not first kind of therapy approved by US FDA that belongs to CDK inhibitors but according to US FDA statement this drug provides targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class.
Breast cancer is one the highly prevailing cancer among women and spreads rapidly. Early detection of such kind of cancers is very important factor in defining prognosis, survival rate and life expectancy. Proper screening and following provided guidelines play important role in prevention and early detection of such disorders.
Verzenio/abemaciclib belongs to a class known as CDK inhibitors (cyclin dependent kinase inhibitors) but it specifically causes inhibition of CDK4 and CDK6. These molecules CDK4 and CDK6 play important role in the development of cancerous cells that's why their inhibition provides better control over disease
progression.
According to health authorities following side effects were observed during clinical trails
Common Side effects
Verzenio/abemaciclib is approved for the treatment of certain advance metastatic cancers like hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer. US FDA approved this in combination with other drug fulvestrant if there is not adequate response after administering endocrine therapy.
Verzenio/abemaciclib is formulated in tablet form for oral administration in following strength 50mg, 100mg, 150mg, 200mg. Recommended dosing frequency of Verzenio/abemaciclib is 200mg twice daily as mono therapy or 150mg twice daily in combination with fulvestrant.
US FDA approved new drug Verzenio that contains active pharmaceutical ingredient abemaciclib for the treatment of certain advance metastatic cancers like hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer. US FDA approved this in combination with other drug fulvestrant if there is not adequate response after administering endocrine therapy.
Though it is not first kind of therapy approved by US FDA that belongs to CDK inhibitors but according to US FDA statement this drug provides targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class.
Breast cancer is one the highly prevailing cancer among women and spreads rapidly. Early detection of such kind of cancers is very important factor in defining prognosis, survival rate and life expectancy. Proper screening and following provided guidelines play important role in prevention and early detection of such disorders.
Verzenio/abemaciclib belongs to a class known as CDK inhibitors (cyclin dependent kinase inhibitors) but it specifically causes inhibition of CDK4 and CDK6. These molecules CDK4 and CDK6 play important role in the development of cancerous cells that's why their inhibition provides better control over disease
progression.
Verzenio/abemaciclib Side effects
According to health authorities following side effects were observed during clinical trails
Common Side effects
- Nausea
- Vomiting
- Abdominal Discomfort
- Diarrhea
- Weakness
- Palpitations
- Low white blood cell count
- Loss of appetite
- Headache
- Â Elevated liver Enzymes
- Clotting (Thrombosis)
- Hypersentivity reaction
- Anaphylaxis
Verzenio/abemaciclib Uses
Verzenio/abemaciclib is approved for the treatment of certain advance metastatic cancers like hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer. US FDA approved this in combination with other drug fulvestrant if there is not adequate response after administering endocrine therapy.
Verzenio/abemaciclib Dosage
Verzenio/abemaciclib is formulated in tablet form for oral administration in following strength 50mg, 100mg, 150mg, 200mg. Recommended dosing frequency of Verzenio/abemaciclib is 200mg twice daily as mono therapy or 150mg twice daily in combination with fulvestrant.
0 Comments
For comments please reply here.......